Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%

European Journal of Ophthalmology

Volumn 9, Issue 4, 1999, Pages 269-275

  Tabbara, Khalid F ^a,b,d   El Sheikh, H F ^a,c   Islam, S M Monowarul ^a   Hammouda, E ^a  

^a The Eye Foundation for Research in Ophthalmology   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c Cairo University   (Egypt)

^d NONE   (Saudi Arabia)

Author keywords

Acute conjunctivitis; Bacterial conjunctivitis; Fluoroquinolones; Lomefloxacin; Ofloxacin; Quinolones

Indexed keywords

EYE DROPS; LOMEFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE IRRITATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033393973     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067219900900403     Document Type: Article

References (37)

1. Sanders DR, Aquavella JV, Hays JC, Jackson WB, Jensen HG, Long DA. New horizons in anti-infective therapy. Ocular Surgery News Supplement to May 1, 1990; 1-15.
2. Miller IM, Vogel R, Cook RTJ, Wittreich J and the worldwide Nofloxacin Ophthalmic Trial Group. Topically administered Norfloxacin compared with topically administered Gentamicin for the treatment of external ocular bacterial infections. Am J Ophthalmol 1992; 113: 638-44.
3. Leibowitz HM. Antibacterial effectiveness of Ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol 1991; 112 (suppl): S29-33.
4. Malminiemi K, Kari O, Latvala M-L, Voutilainen R, Miettinen A, Jauch A. Topical lomefloxacin twice daily compared with fucidic acid in acute bacterial conjunctivitis. Acta Ophthalmol Scand 1996; 74: 280-4.
5. Lesher GY, Froelich EJ, Gruett MD, et al. 1,8-Naphthyridine derivatives: a new class of chemotherapeutic agents. J Med Chem 1962; 5: 1063-5.
6. Fernandes PB. Mode of action and in vitro and in vivo activities of fluoroquinolones. J Clin Pharmacol 1998; 28: 156-68.
7. Cozzarelli NR. DNA gyrase and supercoiling of DNA. Science 1980; 207: 953-60.
8. Shen LL, Pernet AG. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: The target of drugs is DNA. Proc Natl Acad Sci 1985; 82: 307-11.
9. Hirose T. Okezaki E, Kato H, Ito Y, Inoue M, Mitsuhashi S. In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother 1987; 31: 854-9.
10. Ng EY, Trucksis M, Hooper DC. Quinolone resistance mutations in topoisomerase IV" Relationship to the flea locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40: 1881-8.
11. Shen LL, Tanaka SK, Chu DTW. Quinolones, 2-pyridones and resistant type II DNA topoisomerases. Curr Pharm Des 1997; 3: 169-76.
12. Wise R, Andrews JM, Ashby JP, Matthews RS. In vitro activity of lomefioxacin, a new quinolone antimicrobial agent in comparison with those of other agents. Antimicrob Agents Chemother 1988; 32: 617-22.
13. Chin N-X, Novelli A, Neu HC. In vitro activity of lomefioxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other agents. Antimicrob Agents Chemother 1988; 32: 656-62.
14. van der Auvera P, Grenier P, Giupezynski Y, Pieranrd D. In vitro activity of lomefioxacin in comparison with perfloxacin and ofloxacin. J Antimicrob Chemother 1989; 23: 209-19.
15. Inderlied CB, Lancero MG, Bermudez LM, Young LS. In vitro activity of lomefioxacin as compared with ciprofloxacin. Diagn Microbiol Infect Dis 1989; 12 (suppi): S17-20.
16. Stratton CW, Weeks LS . Bactericidal activity of lomefloxacin SC4711 (NY-198) and ciprofloxacin against selected pathogens. Diagn Microbiol Infect Dis 1989; 12 (Suppl): 29S-34.
17. Stone JW, Andrews JM, Ashby JP, Griggs D, Wise R. Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother 1988; 32: 1508-10.
18. Dette GA, Knothe H. In vitro evaluation of lomefloxacin. Arzneimittelforschung Drug Res 1989; 39: 832-5.
19. Ooishi M, Oomomo A, Sakaue F, et al. Studies on intraocular penetration of NY198 (Lomefloxacin) eye drops. Acta Soc Ophthalmol Jpn 1988; 92: 1825-32.
20. Kam K-M, Lo K-K, Lai C-F, Lee Y-S, Chan C-B. Ofloxacin susceptibilities of 5,667 Neisseria gonorrheae strains isolated in Hong Kong. Antimicrob Agents Chemother 1993; 37: 2007-8.
21. Smith JT, Lewin CS. Chemistry and mechanisms of action of the quinolone antibacterials. In: Andriole VT, ed. The Quinolones. London: Academic Press, 1988; 23-82.
22. Wolfson JS, Hooper DC, Swartz MN. Mechanisms of action and resistance to quinolone antimicrobial agents. In: Wolfson JS, Hooper DC, eds. Quinolone antimicrobial agents. Washington: ASM, 1989; 5-34.
23. Roskowski W, Ko HL, Roszkowski P, Ciborowski J, Jeljaszewics J, Pulverer G. Effects of ciprofloxacin on the humoral and cellular immune responses in Balb/C-mice. Zbl Bakt Hyg 1986; A262; 396-402.
24. Forsgren A, Schlossman SF, Tedder TF. 4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro. Antimicrob Agents Chemother 1987; 31: 768-73.
25. Roche Y, Gougerot-pocidalo MA, Fay M, Etienne O, Forest N, Pocidalo JJ. Comparative effects of quinolones on human mononuclear leukocyte functions. J Antimicrob Chemother 1987; 19: 781-90.
26. Gollopudi SVS, Prabhala RH, Thedepalli H. Effect of ciprofloxacin on mitogen stimulated lymphocyte proliferation. Antimicrob Agents Chemother 1986; 29: 337-8.
27. Lombard JY, Descotes J, Evreux JC. Polymorphonuclear leucocyte chemotaxis little affected by three quinolones in vitro. J Antimicrob Chemother 1987; 20: 614-5.
28. Perea EJ, Garcia I, Pascual A. Comparative penetration of lomefloxacin and other quinolones into human phagocytes. Am J Med 1992; 92 (suppl): S48-51.
29. Pruul H, McDonald PJ. Lomefloxacin-induced modification of the kinetics of growth of Gram-negative bacteria and susceptibility to phagocytic killing by human neutrophils. J Antimicrob Chemother 1990; 25: 91-101.
30. Jimenez T, Peman J, Canton E. Actividad Intrafagocitica Del Lemofloxacino. Rev Esp Quimioter 1994; 712: 142-5.
31. Montero J, Casado A, Vigo F, Pastor JC, Alio JL, Soler F, Perea E, Escartin P, Jauch A. Treatment of patients with acute bacterial conjunctivitis with Lomefloxacin 0.3% b.i.d. or Gentamicin 0.3% b.i.d. Eur J Clin Research 1997.
32. Wadworth AN, Goa KL. Lomefloxacin - a review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs (Adis Int) 1991; 32: 1018-60.
33. Yokota T, Suzuki E, Arai K. NY-198, a novel new quinolone, its in vitro antibacterial activity, cytotoxicity for mammalian cells, and synergy of bactericidal activity with mouse cultured macrophages. Chemotherapy 1988; 36 (suppl): S25-35.
34. Debbia E, Pesce A, Schito GC. In vitro assessment of the postantibiotic effect of Lomefloxacin against grampositive and gram-negative pathogens. Am J Med 1992; 92 (suppl): S45-7.
35. Fukuda M, Chou JS, Sasaki K. Intraocular dynamic of a new antibacterial derivative of pyridone carboxylic acid (NY-198). Folia Ophthalmol Jpn 1989; 40: 72-6.
36. Kodama T. Penetration of lomefloxacin ophthalmic solution (NY-198) into the human aqueous humor. Jpn Rev Ophthalmol 1991; 85: 493-5.
37. Nos-Barbera S, Portoles M, Igual A, Fernandez-Piugcarbo E, Diez-Noguera A. A method to evaluate the activity of antimicrobial agents in a model of induced bacterial keratitis. Proceedings of the 8th International Society for Eye Research (ICER), San Francisco, USA. April 9, 1988; 5: 11.